109 related articles for article (PubMed ID: 11761457)
1. Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Shi J; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Nov; 48(5):389-97. PubMed ID: 11761457
[TBL] [Abstract][Full Text] [Related]
2. 5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.
Al Safarjalani ON; Zhou XJ; Rais RH; Shi J; Schinazi RF; Naguib FN; El Kouni MH
Cancer Chemother Pharmacol; 2005 Jun; 55(6):541-51. PubMed ID: 15729584
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for chemotherapy.
Al Safarjalani ON; Zhou XJ; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2001 Aug; 48(2):145-50. PubMed ID: 11565561
[TBL] [Abstract][Full Text] [Related]
4. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
5. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy.
Ashour OM; Al Safarjalani ON; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 45(5):351-61. PubMed ID: 10803917
[TBL] [Abstract][Full Text] [Related]
6. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2',3',5'-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Cancer Chemother Pharmacol; 2000; 46(3):235-40. PubMed ID: 11021741
[TBL] [Abstract][Full Text] [Related]
7. 5-(m-Benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Implications for chemotherapy.
Ashour OM; Naguib FN; el Kouni MH
Biochem Pharmacol; 1996 Jun; 51(12):1601-11. PubMed ID: 8687475
[TBL] [Abstract][Full Text] [Related]
8. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
9. 5-phenylthioacyclouridine: a potent and specific inhibitor of uridine phosphorylase.
el Kouni MH; Goudgaon NM; Rafeeq M; Al Safarjalani ON; Schinazi RF; Naguib FN
Biochem Pharmacol; 2000 Sep; 60(6):851-6. PubMed ID: 10930540
[TBL] [Abstract][Full Text] [Related]
10. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.
Sommadossi JP; Cretton EM; Kidd LB; McClure HM; Anderson DC; el Kouni MH
Cancer Chemother Pharmacol; 1995; 37(1-2):14-22. PubMed ID: 7497584
[TBL] [Abstract][Full Text] [Related]
11. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the anti-tumor efficacy of 5-fluoro-2'-deoxyuridine against murine colon tumor C26-10.
Ashour OM; Naguib FN; Goudgaon NM; Schinazi RF; el Kouni MH
Biochem Pharmacol; 2000 Sep; 60(5):687-92. PubMed ID: 10927027
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor.
Pizzorno G; Yee L; Burtness BA; Marsh JC; Darnowski JW; Chu MY; Chu SH; Chu E; Leffert JJ; Handschumacher RE; Calabresi P
Clin Cancer Res; 1998 May; 4(5):1165-75. PubMed ID: 9607574
[TBL] [Abstract][Full Text] [Related]
13. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor, and 2',3',5'-tri-O-acetyluridine, a prodrug of uridine.
Ashour OM; Naguib FN; Panzica RP; Al Safarjalani ON; el Kouni MH
Biochem Pharmacol; 2000 Aug; 60(3):427-31. PubMed ID: 10856438
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of nucleobase ligands of uridine phosphorylase from Toxoplasma gondii.
Iltzsch MH; Klenk EE
Biochem Pharmacol; 1993 Nov; 46(10):1849-58. PubMed ID: 8250971
[TBL] [Abstract][Full Text] [Related]
15. Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.
Peters GJ; van Groeningen CJ; Laurensse EJ; Lankelma J; Leyva A; Pinedo HM
Cancer Chemother Pharmacol; 1987; 20(2):101-8. PubMed ID: 3664929
[TBL] [Abstract][Full Text] [Related]
16. Species-dependent differences in the biochemical effects and metabolism of 5-benzylacyclouridine.
Davis ST; Joyner SS; Chandrasurin P; Baccanari DP
Biochem Pharmacol; 1993 Jan; 45(1):173-81. PubMed ID: 8424810
[TBL] [Abstract][Full Text] [Related]
17. Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.
Martin DS; Stolfi RL; Sawyer RC
Cancer Chemother Pharmacol; 1989; 24(1):9-14. PubMed ID: 2720896
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of uridine phosphorylase: synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils.
Orr GF; Musso DL; Boswell GE; Kelley JL; Joyner SS; Davis ST; Baccanari DP
J Med Chem; 1995 Sep; 38(19):3850-6. PubMed ID: 7562916
[TBL] [Abstract][Full Text] [Related]
19. Effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from Toxoplasma gondii.
el Kouni MH; Naguib FN; Panzica RP; Otter BA; Chu SH; Gosselin G; Chu CK; Schinazi RF; Shealy YF; Goudgaon N; Ozerov AA; Ueda T; Iltzsch MH
Biochem Pharmacol; 1996 Jun; 51(12):1687-700. PubMed ID: 8687484
[TBL] [Abstract][Full Text] [Related]
20. Tissue-specific expansion of uridine pools in mice. Effects of benzylacyclouridine, dipyridamole and exogenous uridine.
Darnowski JW; Handschumacher RE; Wiegand RA; Goulette FA; Calabresi P
Biochem Pharmacol; 1991 Jun; 41(12):2031-6. PubMed ID: 2039551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
